A recombinant prime, peptide boost vaccination strategy can focus the immune response on to more than one epitope even though these may not be immunodominant in the complex immunogen

Vaccine

Volumn 15, Issue 15, 1997, Pages 1661-1669

  Davis, David ^a,b   Morein, Bror ^c   Åkerblom, Lennart ^c   Lövgren Bengtsson, Karin ^c   Van Gils, Mariëlle E ^d   Bogers, Willy M J M ^d   Teeuwsen, Vera J P ^d   Heeney, Jonathan L ^d  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c NATIONAL VETERINARY INSTITUTE   (Sweden)

^d BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

Avoiding enhancement; Candidate vaccine; HIV 1 envelope glycoprotein; Neutralization escape; Peptide boosting

Indexed keywords

ANTIGEN; EPITOPE; GLYCOPROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ISCOM; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRUS NEUTRALIZATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HUMANS; IMMUNIZATION, SECONDARY; MACACA MULATTA; MOLECULAR SEQUENCE DATA; VACCINES, SYNTHETIC;

EID: 0030843999     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00084-4     Document Type: Article

References (43)

1. Emini, E.A., Jameson, B.A. and Wimmer, E. Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides. Nature 1983, 304, 699-703.
2. Girard, M., Kienny, M.-P., Pinter, A., Barré-Sinoussi, F., Nara, P., Kolbe, H., Kusumi, K., Chaput, A., Reinhart, T., Muchmore, E., Ronco, J., Kacsorek, M., Gomard, E., Gluckman, J.C. and Fultz, P.N. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proceedings of the National Academy of Sciences of the United States of America 1991, 88, 542-546.
3. Girard, M., Meignier, B., Barré-Sinouissi, F., Kieny, M.-P., Matthews, T., Muchmore, E., Nara, P.L., Wei, Q., Rimsky, L., Weinhold, K. and Fultz, P.N. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. Journal of Virology 1995, 69, 6239-6248.
4. H2 immunity (submitted for publication, Science)
5. Anderson, K.P., Lucas, C., Hanson, C.V., Londe, H.F., Izu, A., Gregory, T., Ammann, A., Berman, P. and Eichberg, J.W. Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein gp120 of HIV-1. Journal of Infectious Diseases 1989, 160, 960-968.
6. Neurath, A.R., Jiang, S., Strick, N., Kolbe, H., Kieny, M.-P., Muchmore, E. and Girard, M. Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins. AIDS Research on Human Retroviruses 1995, 7, 813-823.
7. Åkerblom, L., Hansen, J.-E.S., Lövgren, K., Saxinger, C. and Morein, B. A system to select a specified antibody response to conformational neutralizing epitopes in the V3 domain of HIV-1 (submitted for publication). AIDS Res. Human Retroviruses.
8. Levy, J.A., Hoffman, A.D., Kramer, S.M., Landis, J.A., Shimabukuro, J.M. and Oshiro, L.S. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 1984, 225, 840-842.
9. Sanchez-Pescador, R., Power, M.D., Barr, B.J., Steimer, K.S., Stempien, M.M., Brown-Shimer, S.L., Gee, W.W., Renard, A., Randolph, A., Levy, J.A., Dina, D. and Luciw, P.A. Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). Science 1985, 227, 484-492.
10. Haigwood, N.L., Barker, C.B., Higgins, K.W., Skiles, P.V., Moore, G.K., Mann, K.A., Lee, D.R. and Eichberg, J.W. Evidence for neutralizing antibodies directed against conformational epitopes of HIV-1 gp120. In Vaccines '90 (Eds Brown, F., Channock, R.M., Ginsberg, H. and Lerner, R.A.). Cold Spring Harbor, New York, 1990, pp. 313-320
11. Barr, P.J., Parkes, D., Sabin, E.A., Power, M.D., Gibson, H.L., Lee-Ng, C.T., Stephans, J.C., George-Nascimento, C., Sanchez-Pescador, R., Hallewell, R.A., Steimer, K.S. and Luciw, P.A. Expression of functional domains of the AIDS-associated retrovirus (ARV) in recombinant microorganisms. UCLA Symposium on Molecular Cell Biology, New Series 1987, 43, 205-219.
12. Steimer, K.S., Puma, J.P., Power, M.D., Powers, M.A., George-Nascimento, C., Stephans, J.C., Levy, J.A., Sanchez-Pescador, R., Luciw, P.A., Barr, P.J. and Hallewell, R.A. Differential antibody responses of individuals infected with AIDS-associated retroviruses surveyed using the viral core antigen p25 gag expressed in bacteria. Virology 1986, 150, 283-290.
13. Mowat, A.M.C.I., Donachie, A.M., Reid, G. and Jarrett, O. Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology 1991, 72, 317-322.
14. Rönnberg, B., Fekadu, M. and Morein, B. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use as iscom-matrix. Vaccine 1995, 13, 1375-1382.
15. Lövgren, K., Lindmark, J., Pipkorn, R. and Morein, B. Antigenic presentation of small molecules and synthetic peptides conjugated to a preformed iscom as carrier. Journal of Immunological Methods 1987, 98, 137-143.
16. Davis, D., Stephens, D.M., Willers, C. and Lachmann, P.J. Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. Journal of General Virology 1990, 71, 2889-2898.
17. Roben, P., Moore, J.P., Thali, M., Sodroski, J., Barbas, C.F. and Burton, D.R. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. Journal of Virology 1994, 68, 4821-4828.
18. Conley, A.J., Gorny, M.K., Kessler, J.A., Boots, L.J., Ossorio-Castro, M., Koenig, S., Lineberger, D.W., Emini, E.A., Williams, C. and Zolla-Pazner, S. Neutralization of primary human immunodeficiency virus type 1 isolates by broadly reactive anti-V3 monoclonal antibody, 447-52D. Journal of Virology 1994, 68, 6994-7000.
19. Gorny, M.K., Moore, J.P., Conley, A.J., Karwowska, S., Sodroski, J., Williams, C., Burda, S., Boots, L.J. and Zolla-Pazner, S. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. Journal of Virology 1994, 68, 8312-8320.
20. Davis, D., Chaudrhri, B., Stephens, D.M., Carne, C.A., Willers, C. and Lachmann, P.J. The immunodominance of epitopes within the transmembrane protein (gp41) of human immunodeficiency virus type 1 may be determined by the host's previous experience to similar epitopes on unrelated antigens. Journal of General Virology 1990, 71, 1975-1983.
21. Davis, D., Stephens, D.M., Carne, C.A. and Lachmann, P.J. Antisera raised to the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope. Journal of General Virology 1993, 74, 2609-2617.
22. Davis, D. HIV-1 candidate vaccines can induce antibodies which share specificity with human monoclonal antibodies capable of neutralizing primary isolates. Vaccine 1996, 14, 353-354.
23. Kostrikis, L.G., Cao, Y., Ngai, H., Moore, J.P. and Ho, D.D. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. Journal of Virology 1996, 70, 445-458.
24. Trischmann, H., Davis, D. and Lachmann, P.J. Lymphotropic strains of human immunodeficiency virus type 1, when complexed to enhancing antibodies, can infect macrophages through the FcγRIII in a CD4 independent manner. AIDS Research on Human Retroviruses 1995, 11, 343-352.
25. McKeating, J.A., Gow, J., Goudsmit, J., Pearl, L., Mulder, C. and Weiss, R.A. Characterization of HIV-1 neutralization escape mutants. AIDS 1989, 3, 777-784.
26. Cheng-Mayer, C., Shioda, T. and Levy, J.A. Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120. Journal of Virology 1991, 65, 6931-6941.
27. Keller, P.M., Arnold, B.A., Shaw, A.R., Tolman, R.L., van Middlesworth, F., Bondy, S., Rusiecki, V.K., Koenig, S., Zolla-Pazner, S., Conard, P., Emini, E.A. and Conley, A.J. Identification of HIV vaccine candidate peptides by screening random phage epitope libraries. Virology 1993, 193, 709-716.
28. Robert-Guroff, M., Reitz, M.S., Robey, W.G. and Gallo, R.C. In vitro generation of an HTLV-III variant by neutralizing antibody. Journal of Immunology 1986, 137, 3306-3309.
29. Narayan, O., Clements, J.E., Kennedy-Stoskopf, S. and Royal, W. Antigenic variation in the lentiviruses that cause visna-madei in sheep and arthritis-encephalitis in goats. In Antigenic Variation in Infectious Diseases (Eds Birkbeck, T.H. and Penn, C.W.). IRK Press, Oxford/Washington, DC, 1986, pp. 25-40
30. Lambkin, R., McLain, L., Jones, S.E., Aldridge, S.L. and Dimmock, N.J. Neutralization escape mutants of type A influenza virus are readily selected by antisera from mice immunized with whole virus: a possible mechanism for antigenic drift. Journal of General Virology 1994, 75, 3493-3502.
31. Homsy, J., Meyer, M. and Levy, J.A. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. Journal of Virology 1990, 64, 1437-1440.
32. Homsy, J., Meyer, M., Tateno, M., Clarkson, S. and Levy, J.A. The Fc and not the CD4 receptor mediates antibody enhancement of HIV infections in human cells. Science 1989, 244, 1357-1360.
33. Stephens, D.M., Eichberg, J.W., Haigwood, N.L., Steimer, K.S., Davis, D. and Lachmann, P.J. Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine. Journal of General Virology 1992, 73, 1099-1106.
34. Wang, C.Y., Looney, D.J., Li, M.L., Walfield, A.M., Ye, J., Hosein, B., Tam, J.P. and Wong-Staal, F. Long-term high-titre neutralizing activity induced by octametic synthetic HIV-1 antigen. Science 1991, 254, 285-288.
35. Eldridge, J.H., Stass, J.K., Meulbroek, J.A., McGhee, J.R., Tice, T.R. and Gilley, R.M. Biodegradable microspheres as a vaccine delivery system. Molecular Immunology 1991, 28, 287-294.
36. Klinman, D.M., Higgins, K.W. and Conover, J. Sequential immunizations with rgp120s from independent isolates of human immunodeficiency virus type 1 induce the preferential expansion of broadly crossreactive B cells. Journal of Experimental Medicine 1991, 173, 881-887.
37. Nara, P.L., Garrity, R.R. and Goudsmit, J. Neutralization of HIV-1: a paradox of humoral proportions. FASEB Journal 1991, 5, 2437-2455.
38. Javaherian, K., Landlois, A.J., LaRosa, G.J., Profy, A.T., Bolognesi, D.P., Herlihy, W.C., Putney, S.D. and Matthews, T.J. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 1990, 250, 1590-1593.
39. Alonso, P.L., Smith, T., Armstrong Schellenberg, J.R.M., Masanja, H., Mwankuye, S., Urassa, H., Bastos de Azevodo, I., Chongela, J., Kobero, S., Menendez, C., Hurt, N., Thomas, M.C., Lyimo, E., Weiss, N.A., Hayes, R., Kitua, A.Y., Lopez, M.C., Kilama, W.L., Teuscher, T. and Tanner, M. Randomized trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in Southern Tanzania. Lancet 1994, 344, 1175-1181.
40. D'Alessandro, U., Leach, A., Drakeley, C.J., Bennett, S., Olaleye, B., Fegan, G.W., Jawara, M., Langerock, P., George, M.O., Targett, G.A.T. and Greenwood, B.M. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 1995, 346, 462-467.
41. Nosten, F., Luxemburger, C., Kyle, D.E., Ballou, W.R., Wittes, J., Wah, E., Chongsuphajaisiddhi, T., Gordon, D.M., White, N.J., Sadroff, J.C., Heppner, D.G. and the Shoklo SPf66 Malaria Vaccine Trial Group. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Lancet 1996, 348, 701-707
42. 3-TT and immunization with sporozoites. Bulletin of the World Health Organization 1990, 68, (Suppl), 33-37.
43. Ramasamy, R., Wijesundere, D.A., Nagendran, K. and Ramasamy, M.S. Antibody and clinical responses in volunteers to immunization with malaria-diphtheria toxoid conjugates. Clinical and Experimental Immunology 1995, 99, 168-174.